Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Chronic Hepatitis C Virus infection
NCT01835938Phase 2Unknown
- Sponsor
- Strasbourg University Hospital
- Start
- May 2013
- Primary completion
- May 2015
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of erlotinib in hepatitis C virus infection, sponsored by Strasbourg University Hospital. Primary endpoints: Virologic response at 14 days and Short-term safety at 14 days. Status: unknown.
02
Drugs
erlotinib
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01835938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835938.